Royalty Pharma PLC (NASDAQ:RPRX) Plans Quarterly Dividend of $0.23

Key Points

• Royalty Pharma declared a quarterly dividend of $0.235 per share, payable September 10 to shareholders of record on August 14. The dividend implies an annualized payout of approximately $0.94 per share and a 1.6% yield.
• The dividend appears well covered, with an 18.7% current payout ratio and an expected future payout ratio of 17.0%; the company has raised its dividend annually for five consecutive years.
• Royalty Pharma’s latest quarterly earnings exceeded expectations, with EPS of $1.32 versus the $1.27 consensus estimate, although revenue of $674.14 million fell short of the $758.93 million forecast.

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) announced a quarterly dividend on Friday, July 17th. Stockholders of record on Friday, August 14th will be given a dividend of 0.235 per share by the biopharmaceutical company on Thursday, September 10th. This represents a c) dividend on an annualized basis and a dividend yield of 1.6%. The ex-dividend date is Friday, August 14th.

Royalty Pharma has raised its dividend by an average of 0.2%annually over the last three years and has increased its dividend every year for the last 5 years. Royalty Pharma has a dividend payout ratio of 18.7% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Royalty Pharma to earn $5.53 per share next year, which means the company should continue to be able to cover its $0.94 annual dividend with an expected future payout ratio of 17.0%.

Royalty Pharma Stock Up 2.0%

NASDAQ:RPRX traded up $1.17 during mid-day trading on Wednesday, hitting $58.96. 151,919 shares of the company's stock traded hands, compared to its average volume of 3,534,631. The company has a fifty day moving average of $56.60 and a 200 day moving average of $50.80. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.80 and a current ratio of 2.80. Royalty Pharma has a twelve month low of $34.08 and a twelve month high of $60.44. The company has a market capitalization of $33.95 billion, a P/E ratio of 40.74, a P/E/G ratio of 1.35 and a beta of 0.43.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.05. Royalty Pharma had a return on equity of 30.01% and a net margin of 32.14%.The business had revenue of $674.14 million during the quarter, compared to the consensus estimate of $758.93 million. On average, analysts forecast that Royalty Pharma will post 5.3 EPS for the current year.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source